ReviewDermato-endocrinology2017
Rosacea: Epidemiology, pathogenesis, and treatment.
Review in Dermato-endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Rosacea andMedicina (Kaunas, Lithuania) · 2026Pooled it
- Pooled it
- Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily.Dermatologic therapy · 2022Trial
- Tangential excision of rhinophyma with electrocautery and healing by secondary intention: A case report.JPRAS open · 2026Article
- The Latest Advances in Rosacea Treatment: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Effects of Botulinum Toxin A on Rosacea-Like Inflammation in an LL-37-Induced Rosacea Mouse Model.Annals of dermatology · 2026Article
- Targeting Neurovascular Inflammation in Rosacea: A Systematic Review of Botulinum Toxin Therapy.Cureus · 2026Review
- Gut Microbiota, Metabolic Markers, and Systemic Inflammation in Young Women with Self-Reported Rosacea: An Exploratory Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Cross-species transcriptomics identify mineralocorticoid receptor pathway overactivation as a central driver of ocular rosacea.Nature communications · 2026Article
- Systemic Inflammatory and Oxidative-Metabolic Alterations in Rosacea: A Cross-Sectional Case-Control Study.Diagnostics (Basel, Switzerland) · 2026Article
- Risk Factor Analysis Based on Disease Severity: Rosacea Disease Management Strategies and Personalized Recommendations.Journal of cosmetic dermatology · 2026Article
- Vicenin-2 attenuates rosacea-like inflammation by inhibiting IL-17RA signaling.Frontiers in pharmacology · 2026Article
- Virtual screening identifies specnuezhenide as a potential therapeutic agent for rosacea via KLK5/TLR4/NF-κB pathway inhibition and metabolic modulation.Frontiers in immunology · 2026Article
- A Real-World Retrospective Cohort Study Evaluating Clinical Effects and Safety of Radiofrequency Microneedling for the Treatment of Rosacea.Clinical, cosmetic and investigational dermatology · 2026Article
- Demographic and clinical features of rosacea in North Jordan: a 10-year university hospital retrospective study.Annals of medicine · 2025Article
- Impact of Oral DFD-29, a Low-Dose Formulation of Minocycline, on Quality of Life in Patients with Rosacea: Results of Two Phase 3 Randomized Controlled Trials.The Journal of clinical and aesthetic dermatology · 2025Article
- Efficacy and Effectiveness of High Molecular Weight Non-Cross-Linked Hyaluronic Acid Plus Succinic Acid Mesotherapy in Rosacea as Adjunct Therapy.Journal of cosmetic dermatology · 2025Article
- Exploring Factors, Comorbidities, Quality of Life (DLQI), and Depression (PHQ-9) in Rosacea Patients: A Comprehensive Analysis.Journal of cosmetic dermatology · 2025Observational
- Serum Zonulin and Its Role in Rosacea Pathogenesis: A Comprehensive Estimation Study.Dermatology practical & conceptual · 2025Article
- Could photobiomodulation be used for treatment of rosacea?Lasers in medical science · 2025Review
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rosacea is a chronic relapsing inflammatory skin disease with a high prevalence among adults of Northern European heritage with fair skin. Symptoms present in various combinations and severity, often fluctuating between periods of exacerbation and remission. Based on morphological characteristics, rosacea is generally classified into four major subtypes: erythematotelangiectatic, papulopustular, phymatous, and ocular. Diverse environmental and endogenous factors have been shown to stimulate an augmented innate immune response and neurovascular dysregulation; however, rosacea's exact pathogenesis is still unclear. An evidence-based approach is essential in delineating differences between the many available treatments. Because of the diverse presentations of rosacea, approaches to treatment must be individualized based on the disease severity, quality-of-life implications, comorbidities, trigger factors, and the patient's commitment to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.